<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01613755</url>
  </required_header>
  <id_info>
    <org_study_id>Met-Dipy001</org_study_id>
    <nct_id>NCT01613755</nct_id>
  </id_info>
  <brief_title>Metformin-Dipyridamole Interaction Trial</brief_title>
  <acronym>MetDipy</acronym>
  <official_title>The Effect of Dipyridamole on the Pharmacokinetics of Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The antihyperglycemic drug metformin and the thrombocyte aggregation inhibitor dipyridamole
      are often used concomitantly in patients with diabetes who have suffered a transient ischemic
      attack or stroke. It has recently been suggested that the gastrointestinal absorption of
      metformin is mediated by the equilibrative nucleoside transporter 4 (hENT4). Dipyridamole has
      been reported to inhibit hENT4 transport in vitro. The aim of this research proposal is to
      study the pharmacokinetic interaction between metformin and dipyridamole. The investigators
      hypothesize that dipyridamole reduces the gastrointestinal absorption of metformin. If this
      hypothesis can be confirmed, then the results of this study can explain in part the high
      variability in plasma metformin concentrations in patients treated with diabetes, and can be
      used to optimize pharmacotherapy in patients with diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The area under the curve of the metformin plasma concentration at several timepoints</measure>
    <time_frame>10 hours after ingestion of last dose of metformin</time_frame>
    <description>The area under the curve of the metformin plasma concentration at t=0, t=1, t=2, t=2.5, t=3, t=3.5, t=4, t=5, t=6, t=8, and t=10 hours after the intake and the Cmax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax) of metformin</measure>
    <time_frame>about 3 hours after intake of last dose of metformin</time_frame>
    <description>Peak plasma concentration (Cmax) of metformin</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Metformin therapy with concomitant use of dipyridamole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 500 mg twice daily for four days in combination with dipyridamole 200 mg twice daily for four days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 500 mg twice daily for four days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin, dipyridamole</intervention_name>
    <description>Metformin 500 mg twice daily for four days Dipyridamole 200 mg twice daily for four days</description>
    <arm_group_label>Metformin therapy with concomitant use of dipyridamole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 500 mg twice daily for four days</description>
    <arm_group_label>Metformin therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-50 years

          -  Written informed consent

        Exclusion Criteria:

          -  Smoking

          -  Hypertension (systolic blood pressure &gt; 140 mmHg and/or diastolic blood pressure &gt; 90
             mmHg)

          -  Diabetes Mellitus (fasting glucose &gt;7.0 mmol/L or random glucose &gt;11 mmol/L)

          -  History of any cardiovascular disease

          -  Concomitant use of medication

          -  Renal dysfunction (MDRD &lt;60 ml/min)

          -  ECG abnormalities, other than firs grade AV-block or right bundle branch block
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>N. Riksen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G. Rongen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2012</study_first_submitted>
  <study_first_submitted_qc>June 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2012</study_first_posted>
  <last_update_submitted>April 26, 2013</last_update_submitted>
  <last_update_submitted_qc>April 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Effect Dipyridamole on pharmacokinetics of metformin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Dipyridamole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

